secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001140361-24-024648
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis Q1 revenue $119M, loss $150M; WAINUA launch delivers $1M royalty; olezarsen NDA filed for FCS
--------------------------------------------------------------------------------

- Q1 total revenue $119M, down 9% YoY from $131M; GAAP operating loss $150M vs $114M prior year.
- SPINRAZA royalties $38M (down from $50M); WAINUA contributed $1M royalty in first partial quarter of launch.
- Cash and short-term investments $2.2B; 2024 financial guidance reaffirmed.
- Olezarsen NDA submitted to FDA for FCS; positive Phase 3 donidalorsen data for HAE, preparing regulatory submissions.
- Pipeline progress: eplontersen fast track for ATTR cardiomyopathy, bepirovirsen fast track for CHB, ION224 positive Phase 2 for MASH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036124024648/0001140361-24-024648-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036124024648/ef20028585_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-024648

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer